Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression

[1]  T. Morikawa,et al.  Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report , 2018, Case Reports in Oncology.

[2]  Jian-hua Chang,et al.  Prognostic and predictive value of serum carcinoembryonic antigen levels in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutations and receiving tyrosine kinase inhibitors , 2017, Oncotarget.

[3]  Bai-jiang Zhang,et al.  Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations , 2017, BMC Cancer.

[4]  Wen-Chien Huang,et al.  Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase Inhibitors and Triggers Epithelial-to-Mesenchymal Transition. , 2017, Cancer research.

[5]  Y. Li,et al.  Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report , 2017, Oncology letters.

[6]  S. Jiang,et al.  Epigenetic Switch between SOX2 and SOX9 Regulates Cancer Cell Plasticity. , 2016, Cancer research.

[7]  Zuxun Cai.  Relationship between serum carcinoembryonic antigen level and epidermal growth factor receptor mutations with the influence on the prognosis of non-small-cell lung cancer patients , 2016, OncoTargets and therapy.

[8]  F. Ciardiello,et al.  Mechanisms of resistance to EGFR-targeted drugs: lung cancer , 2016, ESMO Open.

[9]  A. Ardizzoni,et al.  CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients , 2015, Tumor Biology.

[10]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Villarreal-Garza,et al.  Usefulness of Serum Carcinoembryonic Antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study , 2013, BMC Cancer.

[12]  T. Nakajima,et al.  Prognostic significance of postoperative serum carcinoembryonic antigen levels in patients with completely resected pathological-stage I non-small cell lung cancer , 2013, Journal of Cardiothoracic Surgery.

[13]  Y. Hu,et al.  Expression and prognostic relevance of tumor carcinoembryonic antigen in stage IB non-small cell lung cancer. , 2012, Journal of thoracic disease.

[14]  J. Sørensen,et al.  Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. , 2012, Lung cancer.

[15]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[16]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[17]  William Pao,et al.  Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation , 2010, Clinical Cancer Research.

[18]  T. Mitsudomi,et al.  Serum carcinoembryonic antigen level as a surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer. , 2010, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[19]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[20]  A. Avilés-Salas,et al.  Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis , 2009, BMC Cancer.

[21]  J. Soh,et al.  Risk Factors for Recurrence and Unfavorable Prognosis in Patients with Stage I Non-small Cell Lung Cancer and a Tumor Diameter of 20 mm or Less , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  T. Kawabe,et al.  Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. , 2006, Lung cancer.

[23]  G. Cavet,et al.  Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients , 2005, Clinical Cancer Research.

[24]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[25]  M. Okada,et al.  Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. , 2004, The Annals of thoracic surgery.

[26]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[27]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[28]  Joachim Schneider,et al.  Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. , 2003, Anticancer research.

[29]  M. Ohta,et al.  Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. , 2002, The Annals of thoracic surgery.

[30]  D. Niewoehner,et al.  Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer. , 1998, The Journal of thoracic and cardiovascular surgery.

[31]  T. Peretz,et al.  Evaluation of tissue polypeptide specific antigen, CYFRA 21‐1, and carcinoembryonic antigen in nonsmall cell lung carcinoma , 1998, Cancer.

[32]  J. Y. Wang,et al.  Value of carcinoembryonic antigen in the management of colorectal cancer , 1994, Diseases of the colon and rectum.

[33]  A. Chevinsky.  CEA in tumors of other than colorectal origin. , 1991, Seminars in surgical oncology.

[34]  J. Beatty,et al.  Clinical value of carcinoembryonic antigen: diagnosis, prognosis, and follow-up of patients with cancer. , 1979, Archives of surgery.

[35]  P. Gold,et al.  SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEM , 1965, The Journal of experimental medicine.